Korro Bio unveiled its OPERA platform, using endogenous ADAR to make targeted A-to-I RNA edits aimed at repairing or enhancing proteins without changing DNA. The approach could broaden RNA-based treatments; the company earlier shared preclinical data for KRRO-121 in UCD.
published
Korro Bio unveiled its OPERA platform, using endogenous ADAR to make targeted A-to-I RNA edits aimed at repairing or enhancing proteins without changing DNA. The approach could broaden RNA-based treatments; the company earlier shared preclinical data for KRRO-
Latest documented BWB result
$META market result
I sold the $META $655 Puts 9/25 for $7.60
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.